High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma

D’Avola, Delia; Villacorta‐Martin, Carlos; Martins-Filho, Sebastião N.; Craig, Amanda; Labgaa, Ismaïl; Felden, Johann von; Allette, Kimaada; Bonaccorso, Antoinette; Tabrizian, Parissa; Hartmann, Boris; Sebra, Robert; Schwartz, Myron; Villanueva, Augusto

doi:10.1038/s41598-018-30047-y

Cited by 70 publications

(53 citation statements)

References 23 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of spheroids formed by CTCs declined greatly when cultured with sorafenib or oxaliplatin. Furthermore, the novel single-cell sequencing technology makes individual CTC profiling possible, which may provide more valuable drug target information and guide individualized treatment in the future clinical practice [12,111,112] .…”

Section: Tumor Monitoring and Guiding Personalized Therapeutic Intervmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide and is associated with poor clinical prognosis, which is mainly caused by tumor recurrence and metastasis. Circulating tumor cells (CTCs) are tumor cells shed into the bloodstream and regarded as the "seeds" of tumor recurrent or metastatic lesions. Over the past decade, the clinical value of CTC analysis has been extensively explored. CTC analysis is a representative form of liquid biopsy, offering a novel solution that can bypass the problems of invasive biopsy procedures, enabling comprehensive, non-invasive, and real-time disease monitoring. In HCC, CTC analysis has facilitated early detection and prognosis prediction, as well as treatment monitoring and therapeutic intervention guiding. In this review, we summarize available literature and provide an overview of CTC biology, detection technologies, and clinical applications in the diagnosis, prognosis prediction, and personalized treatment of HCC.

show abstract

Section: Tumor Monitoring and Guiding Personalized Therapeutic Intervmentioning

confidence: 99%

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Wang¹,

Yang²

2020

View full text Add to dashboard Cite

show abstract

“…( 61 ) The main limitation of these technologies is the relatively low sensitivity and lack of reproducibility across different technologies. ( 62 ) The use of single‐cell RNA sequencing technologies has been tested in HCC to further define the molecular features correlated with the metastatic capacity of CTCs, ( 63 ) but additional data in the LT setting are still needed.…”

Section: Molecular Biomarkers For Hcc Risk Stratification In Ltmentioning

confidence: 99%

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Felden¹,

Villanueva

2020

Liver Transpl

Self Cite

View full text Add to dashboard Cite

Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted withinMilan criteria have outstanding outcomes with a 5-and 10-year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor. There are also several studies showing how a subgroup of patients with tumors outside the Milan criteria might achieve comparable outcomes to patients within Milan criteria. In other words, the size and number of tumor nodules does not always reflect tumor biology, which could be better captured using molecular proxies for cancer aggressiveness. Over the last decade, we have significantly improved our understanding of the molecular landscape of early stage HCC. This includes the development of molecular classification, identification of prognostic and mutational signatures, and potential mechanisms of hepatocarcinogenesis. Some molecular markers have already proven useful to predict tumor-related outcomes in HCC patients after LT. Most of these analyses are limited to tissue-derived biomarkers, which limits their implementation in clinical practice because tissue biopsy is not required for HCC diagnosis. Minimally invasive alternative tools, such as liquid biopsy, are being increasingly explored and could help to individualize risk stratification for patients with HCC who will benefit from LT despite being outside the accepted clinical criteria.Liver Transplantation 26 823-831 2020 AASLD.

show abstract

“…Besides genomic profiling, next generation sequencing technique also promotes rapid development of RNA sequence (RNA‐seq) in the past few years. RNA profiling of single CTCs may help to reveal their biology and role in the metastatic process . Sandberg and co‐workers developed a robust method for single‐cell full‐length mRNA‐seq, known as Smart‐seq, which possessed a prominent merit of improved transcriptome coverage .…”

Section: Single Ctc Analysismentioning

confidence: 99%

Beyond Capture: Circulating Tumor Cell Release and Single‐Cell Analysis

Sharma

et al. 2019

Small Methods

View full text Add to dashboard Cite

As the most promising “liquid biopsy”, analysis of circulating tumor cells (CTCs) provides noninvasive access to obtain biological information of solid tumors. It not only advances the understanding of the mechanisms underlying tumor metastasis, relapse, and chemoresistance, but also promotes the development of precision medicine. Over the past decade, the rapid advances in micro/nanomaterials and microfluidics have overcome the technical challenges of capturing CTCs, allowing efficient enrichment and sensitive detection. Beyond the capture of CTCs, major challenges of in‐depth CTC analysis are the release of CTCs from capture platforms and the inherent heterogeneity in CTCs. A variety of technologies have now emerged for release and single‐cell analysis of CTCs. This review focuses on recent progress along this direction. First, different release strategies are outlined and discussed, including their design principles and characteristics (merits and limitations). Then, existing methods for single CTC analysis at the genomic, transcriptomic, proteomic, and functional level are summarized. Finally, some perspectives are provided on current development trends, future research directions, and challenges of CTC studies.

show abstract

High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma

Cited by 70 publications

References 23 publications

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Detection of circulating tumor cells in hepatocellular carcinoma: applications in diagnosis, prognosis prediction and personalized treatment

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma

Beyond Capture: Circulating Tumor Cell Release and Single‐Cell Analysis

Contact Info

Product

Resources

About